Company news: Covidien, GfK and Springer Science+Business Media

Share this article:

Covidien said it plans to spin off its $2-billion pharmaceuticals business into a standalone public company. The business is one of the world's largest producers of bulk acetaminophen and is the largest US supplier of opioid pain medications, including Exalgo, launched in 2010. About two-thirds of sales are derived from the US market. Following a spin-off, which Covidien said could take about 18 months to complete, the resulting Covidien medical products business would have annual sales of about $9.6 billion, representing 80% of the firm's sales.

Research giant GfK said it is acquiring Knowledge Networks, a provider of digital research in the US. Terms were not disclosed. The company plans to combine Knowledge Networks' physician's consulting network panel with its own US healthcare panel, promising to improve access to difficult-to-reach specialists, including allied health professionals, such as dentists, NPs, PAs and surgical groups. Simon Kooyman, CEO of Knowledge Networks, will assume the role of chief operations officer of GfK Custom Research North America, pursuant to the deal.

Springer Science+Business Media signed a three-year agreement with the American Society of Clinical Oncology (ASCO) to become the exclusive supplier of reprints from articles published in ASCO's Journal of Clinical Oncology and Journal of Oncology Practice for areas including North and South America. Under the agreement, effective January 1, Springer will also represent licensing for the ASCO Annual Meeting abstracts and Educational Book, virtual meeting content, symposia proceedings patient materials and ASCO University—the society's online learning environment.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

AstraZeneca takes on pediatricians

The American Academy of Pediatricians says an AstraZeneca drug for preemies should be used less often, and the drugmaker is fighting back with an ad campaign that says the new guidelines put too many at risk.

UK generic use soared in 2013

Generics made up almost 75% of prescriptions in the United Kingdom last year.

GSK refutes consumer spin-off rumor

The company refutes a Financial Times rumor that one was happening soonish.